Financial Performance & Growth - NeuroPace's 2024 revenue reached $79.9 million, demonstrating a 22% year-over-year growth[12] - Q3 2025 revenue was $27.4 million, a 30% increase year-over-year[15] - Gross margin in Q3 2025 was 77.4%, a 417 bps increase year-over-year[15] - FY 2025 revenue guidance is projected to be between $97 million and $98 million, representing an 18%-23% growth[64] RNS System & Clinical Data - The RNS System has been implanted in over 6,000 patients[12] - The RNS System demonstrated a 75% median seizure reduction at 9 years in the original FDA study results[28] - The FDA post-approval study results showed an 82% median seizure reduction at 3+ years[28] Market Opportunity & Expansion - The annual target market opportunity is estimated to be over $3.5 billion[12] - The company is targeting a $55 billion+ total addressable market (TAM) for drug-resistant epilepsy (DRE)[41] - There are approximately 1.2 million people in the U S with drug-resistant epilepsy[18]